Avacta Group PLC Issue of Equity (2821H)
November 30 2015 - 2:00AM
UK Regulatory
TIDMAVCT
RNS Number : 2821H
Avacta Group PLC
30 November 2015
30 November 2015
Avacta Group plc
("Avacta", the "Company" or the "Group")
Issue of Equity
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, today announces that
2,600,000 Ordinary Shares of 0.1p ("new Ordinary Shares") have been
issued by the Company pursuant to the exercise of share
options.
Application has been made for the new Ordinary Shares to be
admitted to trading on AIM and dealings are expected to commence on
3 December 2015.
The total number of Ordinary Shares in issue following the above
issue will be 6,746,245,954 each with voting rights. No Ordinary
Shares are held in Treasury.
The above figure of 6,746,245,954 shares may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FSA's
Disclosure and Transparency Rules.
- Ends -
For further information:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tim Sykes, Chief Financial Officer
Numis Securities Limited Tel: +44 (0)
Michael Meade / Freddie Barnfield 207 260 1000
- Nominated Adviser www.numiscorp.com
James Black - Corporate Broking
Media Enquiries Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Natalie Garland-Collins avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. The Affimer technology has been designed to
address many of these negative performance issues, principally: the
time taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. The Affimer technology is based on a small protein
that can be quickly generated to bind with high specificity and
affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on oncology and bleeding disorders as well as
several partnered development programmes. Avacta is commercialising
Affimer reagents through custom Affimer services to provide bespoke
solutions to customers and via a growing on-line catalogue of
Affimer reagents.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEUBSKRVAAAUAA
(END) Dow Jones Newswires
November 30, 2015 02:00 ET (07:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Sep 2023 to Sep 2024